We use cookies to ensure our website works properly and to personalise your experience. Cookies policy
1,2,4,5 Deparment of Pharmacology, Pravara Rural Education Society’s College of Pharmacy (For Women), Chincholi, Nashik- 422102
3 Bachelor of Pharmacy Hon. Shri. Babanrao Pachpute Vichardhara Trust's Group of Institutions Faculty of Pharmacy Kasti-414701.
One of the most common neuropsychiatric disorders in the world is anxiety disorders, which are complex in nature due to a complex interaction of neurochemical, inflammatory, and environmental factors. The emerging evidence reveals the central role of the gut-brain axis in regulating emotional and behavioral responses by a two-way communication between the gastrointestinal tract and the central nervous system. The dysregulation of gut microbiota has been strongly linked to the increased oxidative stress, neuroinflammation, and neurotransmitter imbalance, which are all associated with the pathogenesis of anxiety disorders.Plant-derived polyphenols have garnered much attention in recent years due to their multifunctional biological properties, including antioxidant, anti-inflammatory, and neuroprotective effects. These bioactive compounds have the potential to mediate the composition of gut microbiota, improve the integrity of the intestinal barrier, and regulate the metabolites produced by microbes, such as short-chain fatty acids, thereby affecting brain function and behavior. Moreover, polyphenols are also known to interact with the major neurotransmitter systems, such as serotonergic and GABAergic systems, which also contributes to their anxiolytic potential.The purpose of this review is to present extensive mechanistic evidence of how plant-derived polyphenols can be used to target the gut-brain axis in anxiety disorders. It also points out the existing preclinical evidence, existing research gaps, and future therapeutic prospects of developing novel, safer, and more effective anxiolytic strategies.
Anxiety disorders are a significant health burden in the world, with millions of people affected by anxiety disorders worldwide, and quality of life greatly impaired. These disorders are distinguished by excessive fear, worry, and behavioral disturbances, and are commonly associated with dysregulation of neurochemical pathways, such as serotonergic, GABAergic, and dopaminergic systems[1]. The conventional pharmacological treatment, which includes benzodiazepines and selective serotonin reuptake inhibitors is widely used but is associated with limitations such as side effects, tolerance, and dependency, making it necessary to explore safer and more effective therapeutic alternatives[2].
Over the past few years, there has been a growing interest in the role of the Gut–brain axis, a complex bidirectional communication network between the gastrointestinal tract and the central nervous system. This system is composed of neural, endocrine, immune, and metabolic pathways and gut microbiota play a central regulatory role[3-4?]. Changes in the composition of gut microbiota, also known as dysbiosis, have been implicated in the pathogenesis of anxiety and other neuropsychiatric disorders through mechanisms that involve increased intestinal permeability, systemic inflammation, and altered neurotransmitter production[5].
The disproportion of the oxidative stress to the antioxidant defense systems is one of the most important pathological characteristics of anxiety disorders. High concentrations of reactive oxygen species (ROS) may cause neuronal damage and dysfunction of synapses, which contribute to anxiety-like behaviors[6]. Also, neuroinflammation mediated by pro-inflammatory cytokines including tumor necrosis factor-alpha (TNF- 6) and interleukin-6 (IL-6) has been demonstrated to disrupt neuronal signaling and worsen behavioral symptoms[7]. It is important to note that these pathological processes are closely interrelated with gut microbiota changes, which further emphasizes the role of the gut–brain axis in the regulation of anxiety.
In this regard, plant-based polyphenols have become promising therapeutic agents because of their various biological activities. Polyphenols Polyphenols are a widespread group of fruits, vegetables, and medicinal plants. These compounds have strong antioxidant and anti-inflammatory effects and have been demonstrated to regulate the composition of gut microbiota, improve intestinal barrier integrity, and control the production of microbial metabolites[8-9]. These processes allow the polyphenols to affect the central nervous system functioning and behavior, indicating that they can be used in the treatment of anxiety disorders.
Therefore, this review aims to explore the mechanistic role of plant-derived polyphenols in targeting the gut–brain axis in anxiety disorders. It also aims at incorporating the latest evidence on oxidative stress, neuroinflammation, and microbiota-mediated pathways, as well as, identifying gaps in research and future directions of the development of novel anxiolytic therapies.
Pathophysiology of Anxiety Disorders:
Multifactorial neuropsychiatric disorders such as anxiety disorders are complex interactions between neurotransmitter systems, neuroendocrine regulation, oxidative stress, and immune responses. These mechanisms need a detailed understanding in order to identify new therapeutic targets.
Dysregulation of neurotransmitter systems, especially gamma-aminobutyric acid (GABA), serotonin (5-HT), and dopamine, is one of the main mechanisms that are involved in anxiety disorders. GABA is the primary inhibitory neurotransmitter in the central nervous system and its decreased activity has been linked with heightened neuronal excitability and anxiety-like behavior[10]. In the same vein, reduced serotonergic transmission has been associated with mood disturbances and anxiety, which is the rationale behind the therapeutic use of selective serotonin reuptake inhibitors (SSRI) [11]. The dopaminergic pathways also play a role in emotional regulation and stress responsiveness, which further influence the state of anxiety [12].
The next important element in the pathophysiology of anxiety is the dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis. Chronic stress causes sustained activation of the HPA axis, which causes increased levels of glucocorticoids like cortisol. Such hormonal imbalance may impair neuronal plasticity, especially in brain regions, such as the hippocampus and amygdala, which are important in processing emotions [13]. The long-term activation of the HPA axis is also linked to the changes in the composition of gut microbiota, which further connects the stress responses to the gut-brain axis [14].
Another important factor that leads to anxiety disorders is oxidative stress. It is caused by the lack of balance between the generation of reactive oxygen species (ROS) and the antioxidant defense mechanisms of the body. Overproduction of ROS may cause cellular damage, such as lipids, proteins, and DNA, resulting in neuronal dysfunction and abnormal behavior[15]. It has been shown that there are higher levels of lipid peroxidation products like malondialdehyde (MDA) and reduced activity of antioxidant enzymes such as superoxide dismutase (SOD) and catalase in anxiety states [16].
Besides oxidative stress, neuroinflammation has a major role in the onset of anxiety disorders. High concentrations of pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF- 6 ) and interleukin-6 (IL-6 ), have been found to change neurotransmitter metabolism and disrupt neural circuits that regulate mood [17]. These inflammatory mediators may traverse the blood-brain barrier and play a role in microglial activation, and thus contribute to the further neuronal damage and behavioral symptoms [18].
Notably, these pathological processes are not independent but are extremely interconnected. As an example, inflammatory pathways can be triggered by oxidative stress, and inflammation can also increase the production of ROS. The gut microbiota composition influences both processes, and the integrated contribution of the gut-brain axis to the pathogenesis of anxiety is highlighted [19]. Thus, a combination of various pathways can offer a better treatment approach in managing anxiety disorders.
Gut–Brain Axis: Mechanistic Overview:
The gut-brain axis is a bidirectional complex communication network that connects the gastrointestinal tract to the central nervous system and integrates neural, endocrine, immune and metabolic signaling pathways. This system is vital in ensuring homeostasis and control of emotional and behavioral responses, such as anxiety-related processes [20].
The neural pathway, especially via the vagus nerve, which links the gut directly to the brain, is one of the main communication pathways in the gut–brain axis. The signals produced by the gut microbiota and intestinal cells are relayed through afferent vagal fibers to the brain regions that are involved in emotional regulation such as the amygdala and hippocampus [21]. The behavioral effects of some probiotic strains have been shown to be abolished by vagotomy, demonstrating the role of vagal signaling in microbiota-mediated brain activity [22].
Besides neural pathways, gut microbiota is central in regulating the brain activity in metabolic processes. Gut bacteria generate different bioactive metabolites, including short-chain fatty acids (SCFAs) like acetate, propionate, and butyrate. These metabolites may have an effect on the brain by modulating neuroinflammation, improving blood-brain barrier integrity, and regulating gene expression related to neurotransmission [23]. SCFAs have also been found to have anti-inflammatory effects, and help to support neuronal health, thus contributing to better behavioral outcomes [24].
Another important element of the gut–brain axis is the immune system. Dysbiosis or the loss of balance in the composition of gut microbiota can result in the increase in the intestinal permeability, also known as the leaky gut. This condition permits entry of bacterial endotoxins like lipopolysaccharides (LPS) into systemic circulation causing immune activation and release of pro-inflammatory cytokines [25]. These cytokines are capable of bypassing the blood-brain barrier and affecting the functioning of the central nervous system, thus contributing to the development of anxiety-like behavior [26].
Moreover, the gut microbiota is directly implicated in the production and control of neurotransmitters. Some bacteria species are capable of producing neurotransmitters, including serotonin, gamma-aminobutyric acid (GABA), and dopamine that are critical to mood and anxiety regulation [27]. It is noteworthy that almost 90 percent of serotonin in the body is produced in the gastrointestinal tract, which is why the gut microbiota plays a crucial role in neurochemical balance [28].
Notably, these pathways are very interconnected and create an integrated network whereby the gut microbiota can influence brain activity and behavior. The disturbances in this system have been closely linked to anxiety and other neuropsychiatric diseases. Thus, the targeting of the gut-brain axis is a promising approach to the development of new therapeutic methods, especially by using plant-derived polyphenols that can alter a variety of components of this axis at the same time.
https://doi.org/10.3390/cells12131735 https://doi.org/10.1038/mp.2016.50
Figure 1: The gut brain axis as a bidirectional pathway between the gut and brain with neural (vagus nerve), immune, endocrinal and microbial signalling.
Role of Plant-Derived Polyphenols in the Gut–Brain Axis:
Plant-derived polyphenols represent a heterogeneous group of bioactive compounds that are widely distributed in fruits, vegetables, tea and medicinal plants. These compounds, such as flavonoids, phenolic acids, and tannins, have been of significant interest because of their potential to regulate the gut–brain axis and impact neuropsychiatric health [29]. It is noteworthy that polyphenols have a low bioavailability in the upper gastrointestinal tract, with a significant proportion of polyphenols being absorbed in the colon, where they interact extensively with gut microbiota [30].
The ability of polyphenols to alter the composition of gut microbiota is one of the most important mechanisms by which polyphenols can influence the gut-brain axis. Polyphenols have the ability to stimulate the development of beneficial microorganisms like Lactobacillus and Bifidobacterium, and prevent the growth of pathogenic microorganisms [31]. This microbial transition increases the synthesis of neuroactive metabolites, such as short-chain fatty acids (SCFAs), which are important in ensuring intestinal and neuronal homeostasis [32].
Besides microbiota modulation, polyphenols have strong antioxidant properties via scavenging of reactive oxygen species (ROS) and amplification of endogenous antioxidant defence systems. The activity assists in lessening neuronal injury caused by oxidative stress, which is a major cause of anxiety disorders [33]. Moreover, polyphenols have the potential to inhibit lipid peroxidation and enhance mitochondrial functioning, which in turn supports neuronal survival and synaptic plasticity [34].
Polyphenols also have a high level of anti-inflammatory effects through the regulation of the important signaling pathways involved in immune responses. They have been demonstrated to inhibit the production of pro-inflammatory cytokines like tumor necrosis factor-alpha (TNF- 6) and interleukin-6 (IL-6) and, therefore, reducing neuroinflammation and improving behavioral outcomes [35]. This anti-inflammatory effect is strongly associated with the regulation of gut microbiota, as microbial imbalance is a key contributor to systemic and central inflammation [36].
The other significant process is the control of neurotransmitter systems. Polyphenols have the potential to modulate the synthesis, release and metabolism of neurotransmitters including serotonin, gamma-aminobutyric acid (GABA) and dopamine, which are important in mood and anxiety regulation [37]. Polyphenols also play a role in their anxiolytic action by increasing serotonergic and GABAergic signaling. Also, polyphenol metabolites of microorganisms can bypass the blood-brain barrier and directly affect neuronal signaling pathways [38].
Notably, these mechanisms are interrelated and they all play a role in the therapeutic potential of polyphenols in anxiety disorders. Plant-derived polyphenols are a promising multi-target approach to modulate the gut-brain axis and improve mental health outcomes.
https://immunenetwork.org/ArticleImage/0078IN/in-21-e20-g005-l.jpg DOI:10.3390/ijms22073356
Figure 2: Polyphenols from plants help regulate the gut–brain axis by reducing oxidative stress and inflammation, balancing gut microbiota, and influencing neurotransmitters.
Mechanistic Pathways Linking Polyphenols, Gut–Brain Axis, and Anxiety Mechanistic Pathways:
The therapeutic effect of plant-derived polyphenols in anxiety disorders is mediated by a number of interconnected mechanisms involving oxidative stress, neuroinflammation, modulation of gut microbiota, and regulation of neurotransmitters, within the gut-brain axis. All these pathways play a role in restoring neuronal homeostasis and behavioral outcomes.
Oxidative Stress Pathway:
Oxidative stress is a key factor in the pathogenesis of anxiety disorders, which is a result of the lack of balance between the production of reactive oxygen species (ROS) and antioxidant defense systems. Uncontrolled ROS may cause damage to neuronal membranes, proteins, and DNA, resulting in a loss of neuronal synaptic plasticity and neuronal dysfunction [39].
Polyphenols have strong antioxidant activity by directly scavenging free radicals and indirectly by enhancing endogenous antioxidant enzymes including superoxide dismutase (SOD), catalase and glutathione peroxidase [40]. Moreover, polyphenols have the potential to activate nuclear factor erythroid 2-related factor 2 (Nrf2), a major controller of cellular antioxidant responses, thereby enhancing neuronal resilience to oxidative damage [41].
Neuroinflammation Pathway:
Neuroinflammation is a key factor in the pathogenesis of anxiety disorders, which is characterized by an increase in the level of pro-inflammatory cytokines TNF-a, IL-6, and IL-1b. These cytokines have the ability to disrupt the metabolism of neurotransmitters and impair neuronal signaling pathways [42].
Polyphenols have also been found to suppress major inflammatory signaling pathways, such as nuclear factor-kappa B (NF-kB), and thus inhibit the expression of pro-inflammatory mediators [43]. Moreover, they are able to inhibit microglial activation, which is central in neuroinflammatory processes, ultimately resulting in improved neuronal functioning and reduced anxiety-like behavior [44].
Gut Microbiota Modulation Pathway:
The gut microbiota is a major controller of the gut-brain axis, which affects peripheral and central processes related to anxiety. Dysbiosis may cause an increase in the intestinal permeability, systemic inflammation, and a change in the production of microbial metabolites [45].
Polyphenols are prebiotic-like compounds that promote the growth of beneficial bacteria like Lactobacillus and Bifidobacterium and inhibit pathogenic species [46]. This modulation improves the production of short-chain fatty acids (SCFAs), which have been shown to improve gut barrier functionality, decrease inflammation, and enhance neuronal signaling [47]. Moreover, microbial metabolism of polyphenols produces bioactive metabolites that may directly affect brain functioning [48].
Neurotransmitter Regulation Pathway:
Anxiety disorders are characterized by imbalance in neurotransmitters, especially in the systems of serotonin, gamma-aminobutyric acid (GABA), and dopamine. The imbalance in these neurotransmitters may result in the change of mood, thinking, and emotional reactions [49].
Polyphenols have been demonstrated to regulate neurotransmitter systems by increasing serotonergic and GABAergic signaling pathways. They can enhance the amount of serotonin by modulating the metabolism of tryptophan and the production of gut-derived serotonin [50]. Moreover, some intestinal microbes activated by polyphenols may generate GABA and other neuroactive substances, which further contributes to the anxiolytic effects [51].
Integrated Mechanism Insight:
All these pathways are closely interrelated, with oxidative stress and inflammation modulating the composition of gut microbiota, and neurotransmitter systems controlled by microbial metabolites. Thus, polyphenols of plant origin are multi-target modulators of the gut-brain axis and provide a comprehensive therapeutic approach to anxiety disorders.
https://doi.org/10.3390/ijms26020614
DOI:10.3390/nu16172856 https://doi.org/10.3390/microorganisms9040723
Figure 3: Integrated mechanistic model illustrating the interaction between oxidative stress, neuroinflammation, gut microbiota, and neurotransmitter imbalance in anxiety disorders and their modulation by plant-derived polyphenols.
Preclinical Evidence from Animal Models:
Animal models Preclinical studies have provided a good amount of evidence in support of the role of plant-derived polyphenols in the modulation of the gut-brain axis and the alleviation of the symptoms of anxiety disorders. These include the chronic unpredictable mild stress (CUMS) model, which is widely known as a reliable and reproducible experimental paradigm of inducing anxiety- and depression-like behaviors in rodents [52]. This model is a simulated chronic exposure to stress in humans and is linked to behavioral, biochemical, and neuroendocrine changes.
The behavioral tests that are commonly used in these studies are the elevated plus maze (EPM), open field test (OFT), and light dark box test. Animals subjected to chronic stress normally show a lack of exploration, high level of immobility and avoidance behavior, which are symptomatic of anxiety-like states [53]. Polyphenol administration has been found to greatly reverse these behavioral deficits, implying their anxiolytic potential.
A number of experimental studies have shown that polyphenol-rich compounds can suppress oxidative stress and neuroinflammation in models of stress. An example of this is the use of flavonoids to reduce the levels of malondialdehyde (MDA) and increase the activities of antioxidant enzymes like superoxide dismutase (SOD) and catalase in brain tissues[54]. Also, the decrease in pro-inflammatory cytokines, such as TNF-a and IL-6, has been noted following the administration of polyphenols, which implies their anti-inflammatory effects [55].
Notably, the preclinical data also indicate the importance of polyphenols in regulating the gut microbiota composition. Research has demonstrated that supplementation with polyphenols has the potential to restore microbial balance by increasing the populations of beneficial bacteria, and reducing the populations of pathogenic species in models of stress-induced microbial imbalance [56]. This modulation is linked to enhanced intestinal barrier integrity and decreased systemic inflammation, further supporting the role of the gut–brain axis in mediating behavioral outcomes.
Moreover, polyphenols were found to affect the levels of neurotransmitters in animal models. Increased serotonin and gamma-aminobutyric acid (GABA), as well as improved regulation of hypothalamic-pituitary-adrenal (HPA) axis, have been reported after polyphenol-rich extracts treatment [57]. These neurochemical modifications are tightly linked with a decrease in anxiety-like behavior and enhancement of cognitive abilities.
Taken together, these results are solid experimental evidence of the therapeutic potential of plant-derived polyphenols in anxiety disorders. These studies are however limited to preclinical models and further clinical studies are necessary to confirm their efficacy and safety in humans.
Research Gap:
Although the current body of research has made significant strides in elucidating the role of the gut–brain axis and plant-derived polyphenols in anxiety disorders, there are several critical gaps that remain in the current body of research. It is necessary to address these limitations in order to translate preclinical results into effective clinical therapies.
To begin with, most of the existing studies are founded on preclinical animal models, including the chronic unpredictable mild stress (CUMS) model, which, although useful, may not be as effective as it is in animal models. The availability of well-designed clinical trials assessing the effectiveness of polyphenols in human populations is lacking, which limits their translational applicability [58].
Secondly, bioavailability and pharmacokinetics of polyphenols are not well understood. Most polyphenols have low absorption in the upper gastrointestinal tract and are extensively metabolised by gut microbiota, leading to the formation of secondary metabolites. Nevertheless, the particular roles of these metabolites in neuroprotective and anxiolytic actions remain not clearly understood [59].
Thirdly, the heterogeneity of gut microbiota between individuals is a significant problem in standardization of therapeutic outcomes. Differences in microbial composition may also have a significant effect on the metabolism and efficacy of polyphenols, resulting in inconsistent responses in different populations [60]. This highlights the need for personalized approaches in gut–brain axis-targeted therapies.
Also, the possible synergistic action of multiple polyphenols is under-researched. Given that dietary sources are usually complex mixtures of bioactive compounds, the understanding of their combined effects may be more realistic and effective in terms of therapeutic strategies [61].
Moreover, the exact molecular pathways connecting the modulation of gut microbiota to changes in the central nervous system are not well understood. Even though the pathways that involve oxidative stress, inflammation, and regulation of neurotransmitters have been identified, their interaction and relative contribution are yet to be studied [62].
Lastly, there is no standardized methodologies in the assessment of the gut microbiota composition, behavioral outcomes, and biochemical markers across studies. This variability reduces the comparability and reproducibility of findings, thus impeding the emergence of evidence-based therapeutic guidelines.
Thus, future studies must be aimed at conducting well-controlled clinical trials, exploring personalized therapeutic approaches, and understanding detailed molecular mechanisms to fully exploit the therapeutic potential of polyphenols in targeting the gut-brain axis.
FUTURE PERSPECTIVES
The increasing knowledge on the gut-brain axis has created new opportunities in the development of new therapeutic interventions to address anxiety disorders. Multi-targeted mechanisms of plant-derived polyphenols make them a promising group of bioactive compounds with high translational potential. Nonetheless, there are a number of areas that need to be explored further to achieve the maximum of their clinical applicability.
The incorporation of personalized medicine strategies is one of the main future directions. Since there is a large inter-individual difference in the composition of gut microbiota, customizing polyphenol-based interventions based on individual microbiome profiles may enhance treatment efficacy and reduce variability in treatment responses [63]. The development of metagenomics and metabolomics may help in identifying certain microbial signatures that are associated with enhanced response to polyphenol therapy.
The other potential opportunity is the creation of novel drug delivery systems to enhance the bioavailability and stability of polyphenols. Novel formulations, including nanoencapsulation, liposomal delivery, and polymer-based carriers, can be used to increase intestinal absorption and targeted delivery to specific locations within the gut, thereby maximizing therapeutic effects [64].
Moreover, it is recommended that future studies be conducted on a large scale, randomized controlled clinical trials to establish the efficacy and safety of polyphenols in human populations. The inclusion of comprehensive outcome measures, such as behavioral assessments, biochemical markers, and gut microbiota profiling should be included in such studies to establish a clear mechanistic relationship between polyphenol intake and improvements in anxiety symptoms [65].
The study of synergistic activity of various polyphenols and other dietary ingredients is also a significant research direction. The use of a combination of bioactive compounds can result in improved therapeutic effects as they can target several pathways at once, therefore, providing a more holistic approach to the management of anxiety disorders [66].
Moreover, new technologies like artificial intelligence and machine learning might be employed to examine the complex data including microbiota composition, metabolic profiles, and behavioral outcomes. Such methods can be used to discover new biomarkers and to streamline treatment plans to address disorders of the gut-brain axis.
Lastly, it is necessary to understand in more detail the molecular mechanisms underlying polyphenol-microbiota-brain interactions. The future research should be directed at clarifying the exact signaling pathways, as well as defining the key molecular targets in mediating the anxiolytic effects of polyphenols. This kind of insight will help in the creation of more focused and effective therapeutic interventions.
CONCLUSION
Anxiety disorders are complex and multifactorial conditions which are characterized by complicated interactions between neurochemical, inflammatory, and environmental factors. The recent developments in the study of the gut-brain axis have underscored its central role in regulating the emotional and behavioral responses, thus offering new insights into the pathogenesis and treatment of anxiety-related disorders.Plant-based polyphenols have become promising therapeutic agents since they can target a variety of interconnected pathways, such as oxidative stress, neuroinflammation, gut microbiota composition, and neurotransmitter regulation. Their ability to act as multi-target modulators of the gut-brain axis makes them a new and, possibly, safer alternative to traditional pharmacological treatments.
The preclinical studies have shown that polyphenols have significant anxiolytic effects supported by the changes in behavioral, biochemical, and neuroendocrine parameters. Nonetheless, even with these promising results, the extrapolation of these findings to clinical practice is still unclear because of the gaps in human studies, bioavailability issues, and variations in individual microbiota profiles.
Consequently, future studies ought to concentrate on properly designed clinical trials, improved delivery systems, and customized therapeutic solutions to maximize the potential of polyphenols in the treatment of anxiety. The comprehensive knowledge of the polyphenol-microbiota-brain interactions will further help to develop specific and effective treatment strategies.
Finally, the application of plant-derived polyphenols to the gut-brain axis is an emerging and promising paradigm in the management of anxiety disorders, and presents new opportunities in the development of new, multi-target therapeutic interventions.
REFERENCES
Snehal Kanase, Kartiki Dome, Shivtej Kanase, Dr. Kiran Kotade, Sangita Bhandare, Targeting the Gut–Brain Axis in Anxiety Disorders: Mechanistic Insights and Therapeutic Potential of Plant-Derived Polyphenols, Int. J. of Pharm. Sci., 2026, Vol 4, Issue 5, 2770-2782, https://doi.org/10.5281/zenodo.20133634
10.5281/zenodo.20133634